Oral semaglutide demonstrates favourable cardiovascular safety profile and signi ... Read more
Oral semaglutide demonstrates greater reductions in both HbA1c and body weight c ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
Oral semaglutide demonstrates favourable cardiovascular safety profile and signi ... Read more
If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.
23 November - Novo Nordisk has announced the headline results from the last global phase 3a trial, PIONEER 6.
“We are very encouraged that PIONEER 6 demonstrated cardiovascular safety as well as a significant reduction in both CV and all-cause mortality following oral semaglutide treatment in people with type 2 diabetes at high cardiovascular risk. Based on the strong clinical data reported throughout the PIONEER clinical trial programme, we have now established a solid efficacy and safety profile for oral semaglutide and we are looking forward to sharing the results with regulatory authorities during 2019,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.
Read all the details about PIONEER 6 and the other completed PIONEER trials: PIONEER 1 - PIONEER 2 - PIONEER 3 - PIONEER 4 + 7 - PIONEER 5 - PIONEER 6 - PIONEER 9
Twenty years after Jacob Sten Petersen embarked upon a career in diabetes research, his own daughter Vita was diagnosed with type 1 diabetes. Here he reflects on his very personal motivation to achieve a cure for type 1 diabetes and on the progress of Novo Nordisk’s stem cell research.
Watch the video with Jacob and Vita and read the full story
Novo Nordisk will establish a manufacturing site in Fremont, California, US to develop and produce stem cell-based therapies. This announcement follows the signing of a long-term lease on a good manufacturing practice (GMP) facility, previously operated by Asterias Biotherapeutics. The site will support Novo Nordisk’s increased commitment to develop stem-cell based therapies within type 1 diabetes and other serious chronic diseases. Once operational in 2019, the facility will fulfil the supply of stem cell-based therapies for Novo Nordisk’s clinical trial programmes.
Read the press release on this topic
Many more people are today affected by chronic non-communicable diseases (NCDs) than by communicable diseases. This is not reflected in resources for health in general and much less in humanitarian crises.
The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally; support for ICRC’s and DRC’s health programmes; 2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.
Read CEO Lars Fruergaard's reflections and more about the partnership
Obesity can seem fairly straightforward to explain – if we consume more calories than we need, we pile on the pounds. But in fact, the problem is much more complex. It seems our bodies are hard-wired to hang on to those extra calories, probably because for thousands of years, it was a basic survival mechanism.
Danish Government and Novo Nordisk have partnered with UN-anchored initiative on non-communicable diseases. The Danish Government and Novo Nordisk have announced grants of 3 and 5 million US dollars respectively to the Defeat-NCD Partnership. The aim is to raise 100 million dollars to fund mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries.
